This ranking evaluates how Fortune 500 companies are deploying AI, and how technology leaders value those investments relative to industry peers.

Fortune AIQ 75

The companies on the Global 500 employ 70.2 million people, and their revenue represents more than one-third of the world’s GDP.

Fortune Global 500

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are computers, internet services, IT services, semiconductors, and software companies.

Fortune Sector Leaders: Technology

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

F500-2023-097-Thermo Fisher Scientific

The biotech firm, known for its COVID-19 test, continued to rake in revenue for the device, making more than $3 billion off COVID-testing alone in 2022. Total revenue shot up 14.5%, nearing $45 billion. 
<ul> 
 	<li>Thermo Fisher kicked off 2023 with its acquisition of diagnostics company The Binding Site in an all-cash transaction of $2.8 billion.</li> 
 	<li>In December 2022, the U.S. Food and Drug Administration granted emergency use authorization for Thermo Fisher’s test to detect monkeypox.</li> 
 	<li>As competitors like Novartis and Biogen announced plans to cut back on R&amp;D projects in early 2023, Thermo Fisher showed signs of continued innovation. New product releases include an instrument to analyze trace elements like toxins in food and beverages as well as an automated digital tool to increase productivity in molecular research.</li> 
</ul>

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

This year’s Fortune 500 marks the 68th running of the list.

F500-2022-092-Thermo Fisher Scientific

A leading provider of life-science-related equipment and services to pharmaceutical, biotech, and government entities, Thermo Fisher Scientific rode a wave of demand in the second year of the pandemic: Among other things, companies making COVID vaccines and treatments continue to rely on its lab equipment. Revenue and profits each grew more than 20% in 2021.

This year’s group delivered stellar revenue and profit growth, but it underperformed the broader stock market.

100 Fastest-Growing Companies

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

<span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;Thermo Fisher Scientific, which sells equipment, software, and services for scientific research, had a stellar 2020, lifted by huge demand for its products, such as PCR tests, during the pandemic. The lab supplier collected $6.6 billion in revenue during the year from sales of instruments and other products to more than 200 customers trying to develop COVID-19 vaccines and treatments. Overall revenue rose 26% to $32 billion, compared with the prior year, while profits soared 73% to $6.4 billion. Even with the COVID vaccine rush behind them, the company is thinking big with its $17.4 billion acquisition of contract research business PPD, which it announced in April.&quot;}" data-sheets-userformat="{&quot;2&quot;:12673,&quot;3&quot;:{&quot;1&quot;:0},&quot;10&quot;:2,&quot;11&quot;:4,&quot;15&quot;:&quot;Calibri&quot;,&quot;16&quot;:12}">Thermo Fisher Scientific, which sells equipment, software, and services for scientific research, had a stellar 2020, lifted by huge demand for its products, such as PCR tests, during the pandemic. The lab supplier collected $6.6 billion in revenue during the year from sales of instruments and other products to more than 200 customers trying to develop COVID-19 vaccines and treatments. Overall revenue rose 26% to $32 billion, compared with the prior year, while profits soared 73% to $6.4 billion. Even with the COVID vaccine rush behind them, the company is thinking big with its $17.4 billion acquisition of contract research business PPD, which it announced in April.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-95-Thermo-Fisher-Scientific-DR2A0394

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-2020-498-Thermo-Fisher-Scientific

This manufacturer of analytical instruments, equipment, software, and services for scientific researchers has more than 75,000 employees around the world.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-119-Thermo-Fisher-Scientific

This manufacturer of analytical instruments, equipment, software, and services for the scientific research industry has more than 75,000 employees around the world.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fastest-growing Companies

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Current Streak

Years on List

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Thermo Fisher Scientific is a global provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services. Founded in 1956, the company has a strong presence in North America, Europe, and the Asia-Pacific region. The company’s operations are structured into four main sections: life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Thermo Fisher Scientific (TMO): Company Profile, Stock Price, News, Rankings

legacy

Thermo Fisher Scientific

thermo fisher scientific

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 20 24 4th Quarter Conference Call. My name is Ezra, and I will be your coordinator today. I would like to introduce our moderator for the call, Mr.

Rafael Tahada, Vice President, Investor Relations. Mr. Tejada, you may begin the call.

Good morning and thank you for joining us. On the call with me today is Mark Casper, our Chairman, President and Chief Executive Officer and Stephen Williamson, Senior Vice President and Chief Financial Officer. Please note this call is being webcast live and will be archived on the Investors section of our website thermofisher.com under the heading News, Events and Presentations until February 13, 2025. A copy of the press release of our Q4 and full year 2024 earnings is available in the Investors section of our website under the heading Financials. So before we begin, let me briefly cover our Safe Harbor statement.

Various remarks that we may make about the company's future expectations, plans and prospects constitute forward looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed in the company's most recent annual report on Form 10 ks and subsequent quarterly reports on Form 10 Q, which are on file with the SEC and available in the Investors section of our website under the heading Financials SEC filings. While we may elect to update forward looking statements at some point in the future, we specifically disclaim any obligation to do so even if our estimate change. Therefore, you should not rely on these forward looking statements as representing our views as of any date subsequent to today. Also, during this call, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP.

A reconciliation of these non GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our Q4 and full year 2024 earnings and also in the Investors section of our website under the heading Financials. So with that, I'll now turn the call over to Mark.

Thank you, Raff. Good morning, everyone, and thanks for joining us today for our Q4 call. As you saw in our press release, we delivered an excellent finish to 2024 with strong revenue and earnings growth. Our 4th quarter results continue to highlight the strength of our operational and commercial execution. As I reflect on our performance for the full year, I'm very proud of our team as they continue to enable the success of our customers.

This resulted in meaningful market share gains and strengthening our trusted partner status with our customers. We are incredibly well positioned for the future. I'll get into more detail later in my remarks, but first let me recap the financials, starting with the quarter. Our revenue in Q4 grew 5% year over year to $11,400,000,000 Our adjusted operating income grew 7% to $2,720,000,000 We expanded our adjusted operating margins by 50 basis points to 23.9 percent and we delivered strong adjusted EPS performance growing adjusted EPS 8% to $6.10 per share in the quarter. Then in terms of our full year results, our revenue was $42,900,000,000 in 20.24.

Adjusted operating income was $9,710,000,000 and adjusted EPS was $21.86 per share. Turning to our performance by end market. In the Q4, underlying market conditions played out as we expected and continue to improve. Our team's excellent execution resulted in revenue performance that was ahead of our expectations and we delivered positive revenue growth across all of our end markets. Let me provide you with some additional context.

Starting with pharma and biotech, we grew in the mid single digits in Q4. This marks the 4th quarter in a row of sequential improvement for this customer segment. Performance in the quarter was led by our research and safety market channel, pharma services and bioproduction businesses. For the full year, pharma and biotech declined in the low single digits, which included a mid single digit headwind from the runoff of vaccine and therapy related revenue. In academic and government, we grew in the high single digits during the quarter and in the low single digits for the full year.

In the quarter, we delivered strong growth in chromatography and mass spectrometry and in our research and safety market channel. In industrial and applied, we grew in the high single digits during the quarter and low single digits for the full year. Growth in the quarter was highlighted by strong performance in our electron microscopy business and in our research and safety market channel. Finally, in diagnostics and healthcare, we grew in the low single digits during the quarter and declined low single digits for the full year. As a reminder, the reported growth in this end market was impacted by the runoff of COVID-nineteen testing related revenue.

During the quarter and the full year, the team delivered good core revenue growth highlighted by our transplant diagnostics, immunodiagnostics and our healthcare market channel. Thanks to our proven growth strategy and our team's excellent execution, we delivered a strong finish across all of our end markets continuing to drive meaningful share gain. As a reminder, our strategy consists of 3 pillars high impact innovation, our trusted partner status with customers and our unparalleled commercial engine. As you know, our growth strategy really resonates with our customers and throughout the year we have continuously strengthened our company to be even more relevant for the future. Let me give you some highlights.

Starting with the first pillar, we had another really terrific year of high impact innovation. Throughout 2024, we launched outstanding products across our businesses that strengthen our industry leadership by enabling our customers to advance their important work. In chromatography and mass spectrometry this year, it was highlighted by the launch of our Thermo Scientific Stellar mass spectrometer, which complements our award winning Thermo Scientific Orbitrap ASTRAL launched in 2023 by validating biomarker candidates of interest to advance clinical research. It's been great to see the significant impact these 2 mass spectrometers are having on advancing science. We also launched the Thermo Scientific Dionix Inuvion Ion Chromatography System, which streamlines environmental testing in industrial and applied settings, helping our customers identify contaminants more efficiently.

In electron microscopy, we launched the Thermo Scientific ILLiad scanning transmission electron microscope, which integrates a number of advanced analytical technologies into a seamless and user friendly workflow to enable the development of advanced materials. In our Biosciences business, we launched the Applied Biosystems MAGMAX sequential DNA RNA kit, which maximizes the isolation of DNA and RNA from blood cancer samples, helping researchers identify unique insights into cancer causing genetic operations. And in bioproduction, we launched the first of its kind bio based film for our single use technologies, developed with plant based material rather than fossil fuel materials. This innovative film provides lower carbon solutions for the production of biologics. We continued this great innovation momentum in the Q4.

In chromatography and mass spectrometry, we launched the Thermo Scientific ICAP MX Series ICP MS, an inductively coupled plasma mass spectrometry platform designed to streamline trace elemental analysis for environmental, food, industrial and research laboratories. And in life science solutions, we introduced new additions to the GIPCO CTS detachable DynaBeats platform to further enhance the development and manufacturing of life changing cell therapies. So another year of innovation that was spectacular and we have an exciting pipeline for the future as well. In 2024, we also continue to strengthen our industry leading commercial engine and deepen our trusted partner status with customers to accelerate their innovation and enhance their productivity. Throughout the year, we expanded our capabilities to meet our current our customers' current and future needs.

This included expanding our pharma services and clinical research capabilities in the U. S. And Europe. To be an even stronger partner for our pharma and biotech customers in the Q4, we introduced our Accelerator Drug Development solution. This truly unique offering leverages our combined CDMO and CRO capabilities to enable our customers to move their critical drug development programs forward with speed, quality and efficiency, helping to improve their return on their R and D investments.

This is a huge value add for our customers and not something they can do alone or with our competitors. Customer feedback has been incredibly positive. We're winning new business and we're excited about the future impact of our accelerated drug development capabilities. We also made significant advancements in partnerships and collaborations with our customers throughout the year. This included our partnership with the National Cancer Institute on the MyloMatch precision medicine umbrella trial, which we announced in July.

And then the FDA approval for Ion Torrent Oncomide DX target test, that's another example of our customer partnerships. This is a next generation sequencing based assay to be used as a companion diagnostic for Servier's first treatment for patients living with glioma, a type of brain cancer. Finally, during the Q4, we entered into a partnership with the University of Arkansas for Medical Sciences to establish the Thermo Fisher Scientific Center of Excellence for proteomics there. These partnerships demonstrate how close we are working with our customers to enable their success and drive meaningful impact for patients. So as you can see, it was another excellent year of advancing our growth strategy.

As always, our PPI business system continued to enable outstanding execution throughout the year. PPI engages and empowers all of our colleagues to find a better way every day. PPI is helping us to drive share gain and improve quality, productivity and customer allegiance. We're also benefiting from the application of generative AI into our PPI business system. Our colleagues around the world are actively deploying GenAI finding new ways to improve the customer experience, streamline internal processes and enhance our products and services.

So not only the PPI contribute to our excellent financial results, it's also helping our team to find new ways to enable our customer success ensuring a very bright future for our company. Turning to capital deployment. We continue to successfully execute our disciplined capital deployment strategy to create tremendous value. We do this through a combination of strategic M and A and substantial return of capital to our shareholders. In 2024, we returned $4,600,000,000 of capital to our shareholders through stock buybacks and dividends, including repurchasing $1,000,000,000 of shares in the Q4.

In terms of M and A, during the year, we completed our acquisition of OlinQ, a leading provider of advanced solutions for proteomics research. OLYNQ is now our proteomic science business. The integration is progressing smoothly and just after quarter end, our OLYNQ technology was selected by the UK Biobank Pharma Proteomics project to support the world's largest human proteomic study of its kind, the latest validation of the value of our capabilities. When I think about our disciplined approach to M and A and our unparalleled track record, it's all about long term value creation for our shareholders. We just celebrated the 2 year anniversary of the acquisition of the binding site, now our protein diagnostics business.

This business performed incredibly well again in 2024, delivering low teens growth, launching new products and driving a great return on investment. This is a recent example of the impact of our proven capital deployment strategy in action. Let me now give you a brief update on our corporate social responsibility initiatives. As a mission driven company, we help to make the world a better place by enabling the important work of our customers. We also have a positive impact by supporting our communities and being a good steward of our planet.

And I'm proud of the actions we took in 2024 in this regard. We made meaningful progress on our net zero roadmap by reducing our emissions, increasing the number of our 0 waste certified sites and launching new greener products and shipping solutions. We also formed new collaborations to improve health outcomes across the globe and we were named one of the world's most innovative companies by Fast Company for our significant contributions in diagnostics that help to advance health equity. Additionally, we continue to advance our STEM education programs reaching more than 180,000 students globally. This helps to ensure we have students engaged in the sciences as ultimately they'll become our future customers.

As I reflect on the year, I'm very proud of what our team accomplished. We have more than 120,000 passionate colleagues who are dedicated to enabling our customer success and advancing science. Together, we continue to build a bright future for our company and I'm very excited about the year ahead. So let me now turn to guidance. Stephen will outline the assumptions that factor into the guidance, but let me quickly cover the highlights.

In 2025, we will once again deliver strong share gain and our PPI business system will enable outstanding execution and we will deliver very strong earnings growth. We're initiating a 2025 revenue guidance in the range of $43,500,000,000 to $44,000,000,000 which assumes 3% to 4% organic growth and an adjusted EPS guidance range of $23.10 to $23.50 which represents 6% to 8% growth in adjusted earnings per share. We're in a great position as we enter 2025. I'm incredibly excited by the opportunities we have with our customers and to create value for all of our stakeholders and build an even brighter future for our company. So to summarize our key takeaways for 2024, our proven growth strategy continued to drive significant share gain.

We continue to elevate our trusted partner status and deepen the relationships with many customers. And this in combination with the power of our PPI business system enabled us to deliver an excellent finish to 2024 with differentiated performance for the quarter and the full year. As we enter 2025 with strong momentum, we are well positioned to deliver excellent financial performance and further strengthen our long term competitive position. With that, I'll now hand the call over to our CFO, Stephen Williamson. Stephen?

Thanks, Mark, and good morning, everyone. As you saw in our press release, we had an excellent Q4. The team executed really well in the quarter and we delivered Q4 financials significantly ahead of what was assumed in the midpoint of our prior guide. We beat Q4 organic growth by just under 2 points, adjusted EPS by $0.14 and we ended the year with very strong free cash flow, delivering $7,300,000,000 for the year. Looking back on 2024, we had a very successful year.

The markets played out as we outlined at the beginning of the year with growth steadily improving each quarter. Our proven growth strategy drove consistent share gain and the PPI business system enabled great execution. All of this enabled us to consistently deliver differentiated financial performance throughout the year all while further strengthening our industry leadership. This puts us in a great position to deliver an excellent 2025. Let me now provide you with some additional details on our Q4 and full year 2024 performance.

Starting with earnings per share. In the quarter, adjusted EPS grew 8% to $6.10 For the full year, we delivered adjusted EPS of $21.86 GAAP EPS in the quarter was $4.78 and for the full year, it was $16.53 On the top line, Q4 reported revenue grew 5% year over year. The components of our reported revenue change included 4% organic growth, a 1% contribution from acquisitions and a slight headwind from foreign exchange. In Q4, core organic revenue increased 5%. For the full year 2024 reported organic and core organic revenue were all flat year over year.

In 2024, we delivered $520,000,000 of pandemic related revenue comprised of approximately $100,000,000 of testing and $420,000,000 from vaccines and therapies. Turning to our organic revenue performance by geography. In Q4, North America grew mid single digits, Europe grew low single digits and Asia Pacific grew high single digits with China growing mid single digits. For the full year, North America declined low single digits, Europe was flat year over year and Asia Pacific and China within Asia Pacific grew low single digits. With respect to our operational performance, we delivered $2,720,000,000 of adjusted operating income in the quarter, an increase of 7% year over year and adjusted operating margin was 23.9%, 50 basis points higher than Q4 last year.

In the quarter, we delivered strong productivity reflecting the continued execution of our cost management initiatives and we drove good volume pull through. This enabled us to fund strategic investments to further advance our industry leadership and offset the expected impact of unfavorable mix this quarter. For the full year, we delivered $9,710,000,000 of adjusted operating income and adjusted operating margin was 22.6%. Total company adjusted gross margin in the quarter was 43.2%, 170 basis points higher than Q4 last year. For the full year, adjusted gross margin was 42.2%, an increase of 100 basis points versus 2023.

Moving on to the details of the P and L. Adjusted SG and A in the quarter was 16.1% of revenue. For the full year, adjusted SG and A was 16.3% of revenue. Total R and D expense was $374,000,000 in Q4. For the full year, R and D expense was $1,390,000,000 up 4% year over year, reflecting our ongoing investments in high impact innovation.

R and D as a percent of our manufacturing revenue for the full year was 7.2%. Looking at our results below the line. Our Q4 net interest expense was $89,000,000 slightly higher than Q4 2023. Net interest expense for the full year was $312,000,000 a decrease of $183,000,000 year over year driven by effective management of our debt portfolio and our strong cash flow. The adjusted tax rate was 10.9% in Q4 and 10.5% for the full year, in line with our expectations.

Average diluted shares were 383,000,000 in Q4, dollars 5,000,000 lower year over year driven by share repurchases net of option dilution. In Q4, we repurchased $1,000,000,000 of shares bringing our total repurchases for 2024 to $4,000,000,000 Turning to free cash flow and the balance sheet. Full year cash flow from operations was $8,700,000,000 and free cash flow was $7,300,000,000 after investing $1,300,000,000 of net capital expenditures. During 2024, we deployed $7,700,000,000 of capital, dollars 3,100,000,000 through M and A with the acquisition of Olinx and $4,600,000,000 through the return of capital to shareholders in the form of $4,000,000,000 of buybacks and approximately $600,000,000 of dividends. We ended the quarter with $5,600,000,000 in cash and short term investments and $31,300,000,000 of total debt.

Our leverage ratio at the end of the quarter was 2.9x gross debt to adjusted adjusted EBITDA and 2.4 times on a net debt basis. And concluding my comments on our total company performance, adjusted ROIC was 11.6%, reflecting the strong returns on investment that we're generating across the company. Now I'll provide some color on the performance of our 4 business segments, starting with Life Sciences Solutions. Q4 reported revenue in this segment grew 5% and organic revenue growth was 3%. Growth in this segment was driven by our Bioproduction and Biosciences businesses.

For the full year, reported revenue declined 3% and organic revenue was 4% lower versus 2023. Q4 adjusted operating income for Life Science Solutions increased 6% and adjusted operating margin was 36.6%, up 40 basis points versus the prior year quarter. During Q4, we delivered strong productivity and good volume pull through, which was partially offset by unfavorable mix and strategic investments. For the full year, adjusted operating income increased 2% and adjusted operating margin was 36.4%, an increase of 2 10 basis points versus 2023. In the Analytical Instruments segment, reported revenue grew 7 percent and organic revenue growth was 8%.

The strong growth in the quarter was led by electron microscopy and chromatography and mass spectrometry businesses. For the full year, both reported revenue and organic revenue grew 3%. In this segment, Q4 adjusted operating income increased 13% and adjusted operating margin was 30.5%, up 170 basis points year over year. In the quarter, we delivered strong productivity and good volume pull through and had favorable FX. This was partially offset by unfavorable mix and strategic investments.

For the full year, adjusted operating income increased 2% and adjusted operating margin was 26.2%, 10 basis points lower than 2023. Since the Specialty Diagnostics in Q4, both reported revenue and organic revenue grew 5%. In Q4, growth in this segment was led by our transplant diagnostics and immunodiagnostics businesses as well as our healthcare market channel. For the full year, reported revenue increased 2% and organic revenue growth was 3%. Q4 adjusted operating income for Specialty Diagnostics increased 3% and adjusted operating margin was 23.6%, 30 basis points lower than Q4 2023.

During the quarter, we delivered good productivity, which is more than offset by strategic investments. For the full year, adjusted operating income was 3% higher than 2023 and adjusted operating margin was 25.7%, an increase of 20 basis points versus the prior year. And finally, in the Baruity Products and Biopharma Services segment, both reported revenue and organic revenue grew 4% versus the prior year quarter. The run off of Vaccines and Therapies revenue had a mid single digit impact on the growth in this segment in Q4. This was offset by very good growth in our Pharma Services business and Research and Safety market channel.

For the full year, reported revenue grew 1% and organic revenue was flat. In this segment, Q4 adjusted operating income increased 3% and adjusted operating margin was 14%, which is flat to Q4 2023. In the quarter, we delivered strong productivity, which is offset by strategic investments and unfavorable mix. For the full year, adjusted operating income declined 8% and adjusted operating margin was 13.3%, which is 130 basis points lower versus 2023. Turning now to guidance.

As Mark outlined, we're initiating a 2025 revenue guidance range of $43,500,000,000 to $44,000,000,000 and an adjusted EPS guidance range of $23.10 to $23.50 This guidance assumes 3% to 4% organic revenue growth, a 1% headwind from the remaining runoff of the pandemic related revenue and a 1.5% revenue headwind from foreign exchange and approximately 90 basis points of adjusted operating margin expansion. All of this will enable a really strong 6% to 8% growth in adjusted EPS. The strength of the guidance reflects our industry leading position, our proven growth strategy and the power of our PPI business system. Let me now provide some more detailed context behind the guide starting with the market growth framing. In 2024, we estimate the industry market growth was down low single digits.

In 2025, we expect the market growth will be better than 2024. We expect market growth will be slightly positive for the year, improving as the year progresses. With this market context and a very strong share gain, we expect organic growth for 2025 to be in the range of 3% to 4%. Now as I commented earlier, this includes a 1% headwind from the remainder of the pandemic runoff, largely in our Clinical Research business. So the underlying total company growth is strong.

Turning to FX. Given recent changes in rates, we're assuming there'll be a headwind from revenue from FX in 2025 of approximately $650,000,000 or 1.5 points. Putting all this together, our top line guidance assumes a 1.5% to 2.5% increase in reported revenue dollars and a 3% to 4% increase in organic revenue. This is a strong step up from 2024. Moving on to the bottom line, we expect to deliver a very strong year of adjusted EPS growth in 2025.

The cost actions we took over the past couple of years are enabling very accretive pull through on the incremental dollars of revenue growth. And we will continue to use the PPI business system to drive productivity and actively manage our cost base. This will enable very strong adjusted operating margin expansion of approximately 90 basis points. Below the line, we're effectively managing our debt and cash positions and taking advantage of great interest rates from cash deposits. And all of this will enable us to deliver adjusted EPS in the range of $23.10 $23.50 which is a very strong 6% to 8% growth for the year.

In terms of potential changes in the macro environment, our guidance is assumed to cover the impact of modest policy changes. And then to help you with your modeling, here are a few additional assumptions behind the guide. We expect approximately $315,000,000 of net interest expense in 2025. We assume that the adjusted income tax rate will be 11.5% in 2025, largely driven by the increased earnings. We're expecting between $1,400,000,000 $1,700,000,000 of net capital expenditures in 2025 and we're assuming free cash flow is in the range of $7,000,000,000 to $7,400,000,000 for the year.

In terms of capital deployment, we're assuming $2,000,000,000 of share buybacks, which were already completed in January. And we estimate that full year average diluted share count will be between 378,000,000 3 79,000,000 shares. And we're assuming we'll return approximately $600,000,000 of capital to shareholders this year through dividends. And finally, I wanted to touch on phasing for Q1. Embedded in the guidance for the year is an assumption that organic growth is flat in Q1 as is adjusted EPS growth in Q1.

This is largely driven by Q1 having 2 less selling days than the prior year quarter and also the phasing of our services revenue within the year. So in conclusion, Q4 capped off a very successful 2024. We expect to continue to manage the company and the opportunities really well in 2025 and are focused on delivering very strong share gains and adjusted EPS growth, enabling excellent financial performance. I look forward to updating you on our progress as we go through the year. With that, I'll turn the call back over to Ralf.

Operator, we're ready for the Q and A portion of the call.

Thank you very much. We will now open the floor for the Q and A session. Our first question comes from Michael Rygiel with Bank of America. Michael, your line is now open. Please go ahead.

Great. Thanks for taking the question. I want to start with something that you flagged briefly there in your closing remarks, Stephen. I think you mentioned modest policy changes built into the guide. I just I'm wondering if you could expand on that and just broadly talk about guidance methodology going into 2025.

It feels like there's a lot more uncertainty, even despite where we're coming from the last couple of years, specifically as it relates to policy and government changes, things like tariffs, NIH, export controls and out a couple of weeks ago on some specific product lines. It's still really tough and too early to say how these will play out. So I'm just wondering if you how much conservatism you build into the guide? Just what are your assumptions on some of these factors? Any additional color you could provide there would be helpful.

So Mike, thanks for the question. Maybe I'll start with a summary actually of kind of the key points and then I'll talk a little bit about the what's going on from a policy perspective, what we embedded in the guide. So, bear with me a little bit. So, when I think about 2024, I think the key points are the team executed very well, right? And the performance was quite differentiated financially and really great momentum with our customers.

Ultimately, the trusted partner status continues to strengthen and positions the company for a bright future. 4th quarter was strong, right? 4% organic growth, 8% growth in EPS, trust EPS. Market conditions, they improved sequentially throughout the year as we expected. We saw positive growth with our expectation for the market in the Q4 and which is what we thought at the beginning of last year.

So the predictability is back in our industry, which is great. When I think about 2025, what we're assuming in the guidance is that the market conditions will continue to strengthen as the year progresses. And we're entering the year with good momentum, right? So our focus, especially given that there's always some level of uncertainty or volatility is to really deliver outstanding EPS growth this year, right? And what we embedded in our guidance is 6% to 8% adjusted EPS growth.

And our best view of the market returning positive organically in terms of total and us delivering 3% to 4%. So that's how we thought about it and we're actively managing the business. So we're very excited about what's the year ahead. Now when I think about policy changes, what's embedded, I think you know deeply our philosophy within reason of changes or within reasons of opportunities, we just manage through it. It becomes it's our job to manage through the unanticipated changes, unless there are such magnitude on the good side of the bad that we would articulate it, right?

So we thought about the environment where today there's a lot of ideas being discussed, but not really yet materialized into any particular policies. What I'm very excited about is the business environment, particularly in the U. S. Is is going to be much more business friendly, with much more of a focus on economic growth. I'm excited that from an M and A perspective, we're likely to see a much more reasonable environment from a regulatory perspective.

And when I think about what our company does and what our customers do, science and medicine are unbelievably important and they're not discretionary and therefore we're excited about it and we'll navigate whatever the environment holds.

Okay. That's helpful, Mark. Thank you. And then for a quick follow-up, in terms of the EPS guide, you're right, better earnings power than we had anticipated, I think most had anticipated. Stephen, I think you said 90 basis points operating margin expansion.

That's very strong, especially given the subdued top line environment. So if you could expand on that, I mean, you mentioned some of the cost actions you've taken in the past, but are there incremental cost actions throughout 2025? Sort of what's the contribution from return to volume growth or maybe mix shift? Just any color on that 90 basis points. Thanks.

Yes. So, Mike, yes, that's the right number. And yes, so really good volume pull through. So when I think about the cost actions we've taken over the past couple of years as we've kind of wind down from the impact of the pandemic and certain areas of our business have had lower volumes than normal, like they're coming back to more normal volumes and we're making sure that the incremental revenue is pulling through at a really high clip. So great to see that and that's embedded in the numbers.

And then it's not just kind of huge cost initiatives, it's about just managing our P and L appropriately and using the PPI business system to be able to do that. So driving very strong productivity and good cost management in the top line environment that we're in for the year. So all those bring that all together, that's what's driving the 90 basis points.

Our next question comes from Rachel Wetensdall with JPMorgan. Rachel, your line is now open. Please go ahead.

Perfect. Good morning, and thank you so much for taking the questions. So, I wanted to follow-up on your answer to Mike's first question around some of the policy changes that we've seen, but specific really to NIH funding. Obviously, we've seen some of the reports the last few weeks around federal funding potentially getting frozen in light of the new administration. So, appreciate that it's early days, and we don't know what some of these policies could ultimately look like.

But at the same time, you would have to imagine that some of these headlines are driving disruption at your customers. So can you walk us through what have you seen since the new administration turnover in terms of customers' behavior, especially within that academic and government market? And how are you actually expecting NIH funding to play out this year?

Yes. So Rachel, it's been 9 days. So in terms of the environment, so I don't think there's any real insight into what's going on. Obviously, there's actually no policies yet, right? There are different things being explored.

And our job is to work collaboratively with the administration. We have a good working relationship certainly with the President's first administration and educate on the importance of our industry and our customers' work and help our customers navigate the environment as well. So from my perspective, I look at we'll help our customers navigate whatever it is. When I think about what's embedded in our guidance, I would say for academic and government globally would be around the company average in terms of what's assumed there and maybe slightly below that because I think pharma and biotech ultimately be a little bit better than the company average this year in terms of the end markets. And when you think about that, about half of our academic and government end market is in the U.

S. And half is, in markets around the world. Interestingly enough, we obviously had an incredibly strong finish in academic and government in the Q4 and it was globally strong, right? It was really every market had really a very strong end to the year. So hopefully that's helpful.

Yes, that is. Thanks for framing that up. To follow-up then, I just wanted to ask on analytical instrumentation. Obviously, that was a really nice quarter in 4Q. So can you walk us through some of the drivers of that beat?

Did you guys see any budget flush trends in the quarter? And was there any benefit from China's stimulus in that number? And then when you look at analytical instrumentation performance for 2025, what are your assumptions regarding China Stimulus contribution? Thank you.

Yes. So Rachel, thanks. Our instrument business once again had a really very positive year, capped off with 8% organic growth in the 4th quarter, 3% growth for the full year. And that's an environment where China was relatively muted for the full year. And as you know, China is a meaningful contributor to the instruments business across the industry.

So team really doing a great job. So what drives that? It's the steady drumbeat of innovation that makes a huge difference. And if you think about even in my remarks, I had to really narrow it down like in terms of the number of products we launched. And you see one instrument after another, you see many other reagents and other products, but we are just on a roll in terms of phenomenal new products, right, whether it's in electron microscopy, whether it's in chromatography and mass spectrometry.

And also in the environmental type applications with ion chromatography, with ICP MS, just really strong and the adoption is great and that's driving meaningful share gain. And the way that our business works is you have relevant innovation customers because of the importance of the work they're doing, they find the funding and that's how it showed up. In terms of stimulus in China and how we thought about it, it's actually nice to see revenue. It wasn't huge, but it was nice to see revenue flow in the instruments business in the Q4. Orders were actually stronger in terms of the orders that we received in China on our instruments and that will obviously ship in 2025.

So similar started to flow there as well. So hopefully it gives you a good sense of the momentum in our instruments business.

Our next question comes from Jack Meehan with Nephron Research. Jack, your line is now open. Please go ahead.

Thank you and good morning. So Stephen, you talked about the phasing of good morning. I forget if it was Stephen or Mark, you talked about the phasing of services revenue during the year. So, albeit, what does the guide assume for PPD clinical research? And can you give us an update, just color on what you're seeing in terms of new authorizations?

Yes. So I'll give the kind of the phasing aspect to it and Mark will give you some more detail about the businesses, so which are both in great shape by the way. So when I think about phasing within the year, I'd say that in Q1 there's some timing and the phasing there. It's largely the pandemic related runoff is more pronounced in Q1 given the comps from last year. So that's the largest piece of the phasing.

There's a little bit of phasing quarter to quarter in terms of the overall phasing for our Pharma Services business. That's kind of a normal noise, but that's probably the largest driver that I talked about in Q1.

Yes. So Jack, when I think about the clinical research capabilities that we have, we're a leader and incredible reputation for innovation and quality and performance for our customers. And when you think about that, one of the things that we've been talking a little bit about, I try to highlight it more today was the combination with our Pharma Services business. And as you know, in Pharma Services, we're a leading provider of contract development and manufacturing capabilities. We spent over 3 years looking at the added value of having those both sets of capabilities, the insights you get, and the impact that you can have for the customers.

And when we launched Accelerator Drug Development, it really is compelling. And what's that really is allowing our customers to do is to leverage our expertise and capabilities to improve the returns on investment of their R and D investments, which is everything in the pharmaceutical and biotech industry. So we're excited. When I think about now more of the details and I think about clinical research, we delivered low single digit organic growth last year, right? The team did a good job, really good job.

And that was to basically grow the business despite the very meaningful headwind from the runoff of vaccines and therapies that was in that business. And when I think to the future about 2025, the business is behaving the way that I would think it should, which is it's a long cycle business. So you saw for the industry, I mean, even with us in low single digit growth last year, that's below the trend line. The trend line for this business is a high single digit growth business. It's the result of 2023's biotech environment and 20232024's pharmaceutical customers actually reprioritizing their portfolios for the IRA.

When I look at authorizations, particularly in the back half of twenty twenty four, they were very strong for us. And when I look at the commercial pipeline that we have this year and the conversations that our executive team is having with our customers, the business actually has a lot of momentum underlying it. If I think about sort of the cycle time of the business that bodes well towards the end of the year and then during 2026. It feels like the conditions will be more measured this year. That's what's embedded in our guidance, kind of similar to what we saw last year.

And then it sets up for great success. So overall, super positive.

Awesome. And you're leading me exactly where I want to go next, which is the guide for 2026. Mostly joking, but can you just talk about as you look

what does the exit rate look like in the Q4? And just more broadly, just like confidence about your ability to get back to the LRP targets that you have?

Yes, Jack, I'll be thrilled to talk about 26% on this call in a year's time. But I understand that you think about that and how you're thinking about the trajectory of the company. Yes, first of all, we're highly confident we're going to get back to the industry long term market growth rate of 4% to 6%. It's just a matter of what's the timing you actually get to that point. And we've proven the ability to consistently drive share gain above that.

So our organic growth will be stronger than markets. And it's great that markets are improving. When I think about what the guide set up is here, going from market down a couple of points to being up slightly, that's a continued improvement. And we expect that, as I said in my prepared remarks, we expect that to continue to increase as we go through the year. The exact ending point of where market growth will be at the end of the year, we'll see that as we get close towards the end of the year.

And as Mark said at the beginning, our job in this period is going through that transition back to normal is to drive really strong adjusted EPS growth and that's exactly what we're setting out to do here for the year ahead.

Our next question comes from Doug Schenkel with Wolfe Research. Doug, your line is now open. Please go ahead.

Thermo Fisher Scientific (TMO) Q4 2024 Earnings Call Transcript

Company Participants